Nigel J. Parr

Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains

Olivier Mirguet, Romain Gosmini, Jérôme Toum et al. · Journal of Medicinal Chemistry · 2013 · 301 citations · Full text

Histone Modifications, Chemoprevention Strategy, Epigenetic Change +22

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy

S. Picaud, O. Fedorov, Angeliki Thanasopoulou et al. · Cancer Research · 2015 · 224 citations · Full text

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

Anastasia Wyce, Gopinath Ganji, Kimberly N. Smitheman et al. · PLoS ONE · 2013 · 203 citations · Full text

Mycn Copy Number, Bet Family Proteins, Cell Regulation +14

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762

Aristeidis Chaidos, Valentina S. Caputo, Katerina Gouvedenou et al. · Blood · 2013 · 202 citations

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

Sarina A. Piha‐Paul, Christine L. Hann, Christopher A. French et al. · JNCI Cancer Spectrum · 2019 · 196 citations · Full text